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Abstract
Concern has been expressed that human papillomavirus (HPV) vaccination programs might 
promote risky sexual behavior through mechanisms such as risk compensation, behavioral 
disinhibition, or perceived endorsement of sexual activity. This study assesses whether HPV 
vaccination status is associated with any differences in selected sexual behaviors among young 
sexually-active women in the US. Our dataset includes young, adult female respondents from 
questionnaire data collected in the National Center for Health Statistics’ National Health and 
Nutrition Examination Survey from 2007 to 2014. The empirical approach implements a doubly 
robust estimation procedure, based on inverse probability of treatment weighting. For robustness, 
we implement several specifications for the propensity model and the outcomes model. We find no 
consistent association between HPV vaccination and condom usage or frequency of sex. 
Specifically, we find no evidence that HPV vaccination is associated with condom usage or with 
whether a person had sex more than 52 or more than 104 times per year. We find inconsistent 
evidence that HPV vaccination is associated with a person having sex more than 12 times per year. 
As in previous research, HPV vaccination does not appear to have a substantive effect on sexual 
behavior among young sexually-active women in the US.
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Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) in 
the US with approximately 79 million persons currently infected and 14 million new 
infections every year (Satterwhite et al., 2013). While the majority of HPV infections 
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resolve on their own with no sequelae, HPV infection can persist and cause disease. HPV 
has been associated with cancer at several anatomic sites: cervical, vaginal, and vulvar 
cancer in females; penile cancer in males; and anal and oropharyngeal cancer in both sexes. 
HPV can also cause cervical precancers, anogenital warts and recurrent respiratory 
papillomatosis (Petrosky et al., 2015). Currently, three HPV vaccines have been approved 
for use in the US: bivalent (Food and Drug Administration, 2009), quadrivalent (Food and 
Drug Administration, 2006) and nonavalent (Food and Drug Administration, 2014). These 
vaccines differ in the number of HPV types, or serotypes, that are prevented. All three 
vaccines prevent HPV types 16 and 18, which cause the majority of HPV-related cancers 
(Meites et al., 2016). For the nonavalent vaccine, recommendations were updated in 2016 to 
a two-dose series for those who initiate vaccination before their 15th birthday (Meites et al., 
2016). Routine HPV vaccination at 11–12 years of age has been recommended in the US for 
females since 2006 and males since 2011 (Markowitz et al., 2014).
Despite the health benefits of HPV vaccination, coverage rates are short of the Healthy 
People 2020 target of 80% coverage for three or more doses of HPV vaccine (Stokley et al., 
2014). Coverage rates for HPV vaccination also lag behind coverage rates for other 
adolescent vaccines (Stokley et al., 2014). As of 2015, 3-dose HPV vaccine coverage rates 
among 13–15-year-olds in the US were estimated at 37% for females and 27% for males 
(Reagan-Steiner et al., 2016). Factors associated with HPV vaccine uptake include the 
strength of physician recommendation (Rosenthal et al., 2011), parent preferences (Brown et 
al., 2010; Freed et al., 2010) and child preferences (Brown et al., 2014). In the President’s 
Cancer Panel, one of the major goals that was discussed was to increase HPV vaccine 
coverage in the US. This goal is supported by the strategy of increasing acceptance of HPV 
vaccines among parents, caregivers, and adolescents (Rimer et al., 2014).
A related reason that has been suggested for relatively low HPV vaccine coverage is the 
perception that HPV vaccination might promote risky sexual behavior through mechanisms 
such as risk compensation, behavioral disinhibition, or perceived endorsement of sexual 
activity. These concerns are consistent to some degree with economic theory, where 
lowering the cost of risky sex (such as with HPV vaccination) would be expected to increase 
the demand for risky sex. Previous public health researchers have found little evidence to 
support this claim (Bednarczyk et al., 2012; Liddon et al., 2012; Mayhew et al., 2014; Smith 
et al., 2014; Jena et al., 2015). Our study investigates this claim using a methodological 
approach and dataset that are new to this issue. In particular, this is the first study we are 
aware of that implements a propensity score-based approach to investigate the relationship 
between vaccination status and sexual behavior. We also investigate relatively subtle changes 
in sexual behavior, including frequency of condom usage and frequency of sexual 
intercourse, available from the National Health and Nutrition Examination Survey 
(NHANES) dataset, which has not been used to investigate the issue of HPV vaccination 
status and risky sexual behavior.
1. Relevant background and literature
The benefits and costs of HPV vaccination have been an object of discussion in the research 
literature (Goldie et al., 2004; Chesson et al., 2008) as well as in the popular media (Brody, 
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2007), with a fair amount of attention paid to aspects of sexual behavior and sexual activity 
(Bednarczyk et al., 2012; Liddon et al., 2012; Mullins et al., 2012; Mayhew et al., 2014; 
Offit, 2014; Smith et al., 2014; Jena et al., 2015). Several studies investigate the relationship 
between vaccination status and medical conditions that are related to sexual behavior, such 
as the diagnosis of other STIs, as captured by electronic health record databases 
(Bednarczyk et al., 2012; Smith et al., 2014; Jena et al., 2015). Other studies use surveys to 
estimate the relationship between vaccination status and levels of specific sexual behaviors, 
such as a number of sexual partners and condom usage (Liddon et al., 2012; Mayhew et al., 
2014). While the majority of studies in this area have been narrow in geographic scope, 
focusing on a single (Bednarczyk et al., 2012; Mayhew et al., 2014; Jena et al., 2015) or 
regional health system (Smith et al., 2014), at least one recent study analyzed a nationally-
representative sample, using the National Center for Health Statistics’ (NCHS’) National 
Survey of Family Growth (Liddon et al., 2012). Recent prevalence assessments of HPV in 
the US came from NCHS’ NHANES (Markowitz et al., 2013, 2016), the data source used in 
our study. The prevalence study found decreasing rates of HPV associated with HPV 
vaccination status but did not investigate into all of the sexual behaviors reported in 
NHANES (i.e., frequency of condom use and frequency of sexual encounters) (Markowitz et 
al., 2013).
In contexts other than HPV vaccination, changes in sexual behaviors have been noted in 
response to changes in factors that affect the potential risks, or ‘costs’, of sexual activity. For 
example, the availability of long-acting reversible contraception can lead to reductions in 
condom use (Steiner et al., 2016). As another example, substantial reductions in risky 
behavior in response to the HIV/AIDS epidemic have been well-documented (Stolte et al., 
2004). The emergence of highly active anti-retroviral therapy for HIV, which could lower the 
perceived consequences of acquiring HIV, was associated with increased frequency of 
unprotected sex and outbreaks of syphilis among men who have sex with men (Chesson and 
Gift, 2008). Concerns about risk compensation and behavioral change complicate many 
prevention efforts of HIV/AIDS (Cassell et al., 2006). While we acknowledge that 
improvements in the prevention and treatment of HIV/AIDS are likely to have much greater 
impacts on the perceived health-risks of sexual activity than would improvements in the 
prevention of HPV, the possibility that the HPV vaccine may change some level of 
perception, attitude, or incentive regarding sexual behavior seems plausible.
Two recent studies (Smith et al., 2014; Moghtaderi and Dor, 2016) have investigated the 
effects that the receipt of the HPV vaccine may have on the subsequent health-risk 
perceptions and health-related behaviors of young women. Both of these studies measured 
subsequent health behaviors by encounters with the health care system related to Pap tests 
(Moghtaderi and Dor, 2016) and related to non-HPV STIs or pregnancy (Smith et al., 2014). 
The Pap test is a cervical screening test used to detect precancers and cancers, which can be 
related to specific types of HPV (Moghtaderi and Dor, 2016). Both of these studies 
implemented regression discontinuity research designs that utilized the adoption of age-
specific HPV vaccination policy as a treatment assignment variable.
While these empirical approaches rely on the plausibly exogenous assignment of treatment 
(i.e., exposure to HPV vaccination) due to the age threshold of vaccination 
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recommendations, the approach used in our study relies on minimizing confounder bias 
through propensity score weighting. Our contribution to this literature includes (1) the 
application of a new methodological approach to this problem, propensity score-based 
empirical approach, and (2) assessment of relatively subtle, or marginal, changes in health 
risk-related behavior including frequency of sexual intercourse and frequency of condom 
usage.
2. Methods
This study assembles an analytical dataset using data from NHANES (Johnson et al., 2013; 
Centers for Disease Control and Prevention, 2015). NHANES is a repeated cross-sectional 
questionnaire survey and medical examination. NHANES respondents are from a 
probability-based sample that is drawn to be nationally representative. The survey 
questionnaire component of NHANES elicits a multitude of factors related to demographics, 
behavioral characteristics and health insurance and utilization, including whether or not a 
respondent received selected vaccinations; see Data section, below, for more information.
For this study, we estimate the probability of an individual receiving an HPV vaccine, 
measured in our data as having received at least one dose of the vaccine. Then using the 
predicted probabilities of vaccination, we construct inverse probability of treatment weights 
(IPTWs). Using an IPTW-balanced sample, we estimate an outcomes model. This estimation 
procedure is said to be doubly robust due to the characteristic that if either the propensity 
model or the outcome model is properly specified, the procedure yields unbiased estimates 
for an average treatment effect (ATE) (Funk et al., 2011; Kaiser and Schmid, 2014). 
Generally, this approach is based on the potential-outcomes framework (Rubin, 1974).
2.1 Conceptual approach
Estimating causal effects using propensity models has been described in detail in the 
literature many times (Hirano and Imbens, 2001; Imbens, 2004; Kaiser and Schmid, 2014). 
Propensity score-based methods have been used in the economic and health research 
literature for many years, investigating critical health issues such issues as cardiovascular 
disease (Deb et al., 2016), drug addiction (Griffin et al., 2014), health communications 
(Leidner, 2014) and cancer treatment (Fujii et al., 2015; Jung et al., 2015). Researchers have 
investigated a variety of issues utilizing methods that combine both propensity score-based 
methods and data from NHANES, such as lead exposure among children (Ahrens et al., 
2016), obesity (Goossens et al., 2015; Ahrens et al., 2016), cancer-related health behavior 
(Jabson et al., 2015) and oral health (Murphy et al., 2014). Using the predicted probability of 
vaccination as an observation weight, two samples are constructed that are comparable 
across all the variables in the model except for vaccination status. Because the only 
observable difference between the two constructed samples is in the treatment variable, this 
approach can illustrate potentially causal associations. The ATE estimates are computed 
following the estimation of an outcomes regression model that controls for a variety of 
relevant individual characteristics, many of which are also used to estimate the propensity 
model. The major limitation of this approach is that the similarities or balance between the 
two constructed samples among attributes that are unmeasurable cannot be assessed. The 
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balance between the two constructed samples and the effect estimates depends on the 
specifications of the propensity score model and the outcomes model. To further ensure our 
estimates are robust to specification choice, we estimate two propensity score models and 
several outcomes models. Another complication of our study is that NHANES data are 
collected from a complex survey design. Building on the work of other propensity-score-
based studies that use complex survey data (DuGoff et al., 2014; Ridgeway et al., 2015), 
both the propensity model and the outcomes model are adjusted for the complex survey 
design of NHANES.
2.1.1 Propensity model—The treatment assignment variable in this study is whether or 
not an NHANES respondent reported ever receiving at least one dose of HPV vaccine. This 
variable is represented by zi, where zi = 1 indicates that individual i was a vaccine recipient 
and zi = 0 indicates no vaccine was received. The vector Xi contains the individual 
characteristics that predict the probability of treatment assignment. In the regression models, 
these individuals are weighted to represent a national sample, using the medical exam 
weights from NHANES. In general, the propensity score (pi(Xi)), or the probability of 
individual i receiving a vaccine conditional on the individual’s characteristics, can be 
represented with the following equations:
pi Xi = Pr zi = 1 Xi (1)
where
0 < pi Xi < 1. (2)
The probability of treatment assignment is a function of the vector of covariates Xi and the 
vector of estimated coefficients A, as in the following:
Pr zi = 1 Xi = α0 + α1x1, i + α2x2, i +⋯+ αkxk, i (3)
where k is the number of covariates in Xi. After estimating the propensity model, the 
predicted values for each individual (pi, predictions are denoted with a hat) are used to 
construct the IPTWs wi
p
 (Hirano and Imbens, 2001). This construction of the IPTWs 
corresponds to the estimation of an ATE.
wi
p =
zi
pi
+
1 − zi
1 − pi
(4)
The final analytical weight (wi) for each individual that is used in the final outcomes 
regression model is the sampling weight from the complex survey design wi
s
 multiplied by 
the IPTW wi
p
 (Ridgeway et al., 2015):
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wi = wi
s × wi
p (5)
2.1.2 Doubly robust estimator—The outcomes model estimates the relationship 
between the outcomes of interest (Yj) and the treatment variable (zi). In addition to the 
treatment variable, a vector of other covariates, denoted as Vi, are also included the 
outcomes model:
Pr Y j, ζ = 1 zi, V i = β0, j, ζ + β1, j, ζv1, i + β2, j, ζv2, i +⋯+ βk, j, ζvk, i
= mζ V i, Bζ
(6)
where ζ = 0 for controls and ζ = 1 for treated, and j is the index for each outcome we 
investigated. The predicted values from the outcomes model are represented by the term 
mζ V i, Bζ , with either treatment or control imposed on the model. The complete 
specification of the doubly robust estimator ΔDR is as follows:
ΔDR =
1
n i = 1
n ziyi − zi − pi m1 V i, B1
pi
− 1n i = 1
n 1 − zi Y i − zi − pi m0 V i, B0
1 − pi
(7)
where n is the sample size; pi is the predicted propensity score; mζ V i, Bζ  are the predictions 
from the outcome model with the treatment variable ζ set to 0 or 1 for the entire sample; Vi 
is the set of covariates; and Bζ are the estimated coefficients from the outcome model with 
the treatment variable ζ set to 0 or 1 (Funk et al., 2011).
2.2 Empirical approach
The dependent variables in the propensity model and outcomes model are all binary. So both 
sets of models can be estimated with any binary limited dependent statistical regression, 
such as a logit or probit. For this study, we use a logit model.
2.2.1 Potential causation model—The general relationships between factors and 
outcomes that are assumed by our empirical specifications are depicted in a conceptual 
diagram (Figure 1). One issue of particular relevance to this study is the relationship 
between prior sexual behavior, HPV vaccination, and sexual behaviors that occur after a 
vaccination is received. For some young women, the decision to receive an HPV vaccination 
might depend on whether or not she is sexually active. For sexually active women, past 
sexual activity is likely correlated to present sexual activity, independent of vaccination 
status. For this reason, we include age at first sexual encounter, intended to control for past 
sexual activity, as a covariate in the propensity model. Other variables, such as having ever 
taken an HIV test and having ever taken birth control pills, are included in health system 
utilization section of Figure 1, but these may also be considered as indicators of sexual 
behavior. In the IPTW samples, the treated and controls are balanced with respect to age at 
Leidner et al. Page 6
Health Econ Policy Law. Author manuscript; available in PMC 2020 November 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
first sexual encounter, having taken an HIV test, and having taken birth control pills. The 
propensity model also includes several variables that we believe are plausibly unrelated to 
sexual behavior decisions, but would likely impact the probability of an individual receiving 
the HPV vaccine. These variables include an indicator variable for the past receipt of 
additional vaccines, including hepatitis A and hepatitis B. While it is possible that hepatitis 
A and B can be transmitted sexually, these are not particularly common events and likely 
constitute a smaller influence on the perceived health risks of sexual activity than would an 
HPV vaccination or concerns over other STIs.
2.2.2 Model specifications—To address the potential for mis-specification, we select 
two specifications for the propensity model (equation (3)) and three or four specifications for 
the outcomes model (equation (6)), depending on the outcome variable. Therefore, for each 
outcome variable, we estimate six or eight regressions, two different propensity models and 
three or four different outcomes models. We refer to the two specifications of the propensity 
model as ‘basic’ and ‘expanded’. In the basic propensity model, the covariate vector Xi 
contains characteristics about each respondent. These characteristics include race/ethnicity 
indicators, age in years at the time of the survey, high school completion status, marital 
status, household poverty-line status, health insurance status, history of taking birth control 
pills, vaccination history for hepatitis A and hepatitis B, history of being tested for HIV, 
smoking status, alcohol consumption status, age in years at time of first sexual experience 
and a time trend. All variables are defined in Table 1. In the expanded propensity model, the 
covariate vector Xi contains the same conceptual components as the basic propensity model, 
but with more refined resolution in some of the variables, where such data are available. As 
one example, the behavioral variables in the basic propensity model include if a respondent 
has ever drank alcohol or ever smoked 100 cigarettes. In the expanded propensity models, 
additional variables, which in this example captured the number of alcohol drinks consumed 
by a respondent per day and if a respondent currently smokes cigarettes every day, are also 
included. Additional details on the model specifications are given in the Supplemental 
Appendix.
We implement up to four specifications of the outcomes model. The labels we give to these 
specifications are ‘basic’, ‘expanded’, ‘basic with sex frequency’, and ‘basic with age fixed 
effects’. Due to limited degrees of freedom, we could not implement the expanded outcomes 
model with sex frequency or with age fixed effects (Table 1). As with the expanded 
propensity model, the expanded outcomes model contains many of the same conceptual 
components as the basic outcomes model but several variables are structured to capture a 
more detailed resolution. The full specification of the basic and expanded models is 
presented in the Supplemental Appendix. Additional specifications of the outcomes model 
include the basic model with sex frequency and the basic model with age fixed effects. The 
basic model with sex frequency includes all the covariates from the basic outcomes model 
with the addition of the three sex frequency indicator variables. The basic model with age 
fixed effects includes indicator variables for every age level.
2.2.3 Inference—Inference for these models is based on 500 bootstrapped replications 
(Wooldridge, 2009), with a replication method based on a rescaled bootstrap procedure 
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described in previous studies (Rao et al., 1992; Cheng et al., 2008) and recently used to 
analyze NHANES data (Talih, 2013, 2015). The upper and lower 95% confidence intervals 
were estimated using the 97.5th and the 2.5th percentiles of the bootstrapped estimates’ 
distribution, respectively. Standard errors were computed directly using the square root of 
the sample variance of the bootstrapped estimates.
3. Data
NHANES is a cross-sectional, complex, multistage probability sampling survey. The survey 
is designed to assess the health and nutritional status of noninstitutionalized civilian US 
residents through interviews and physical examinations. The survey examines a nationally 
representative sample of about 5000 persons each year, and data are released in 2-year cycles 
(Johnson et al., 2013). The dataset used in this study comes from four NHANES cycles, 
2007–2008, 2009–2010, 2011–2012 and 2013–2014. This study looks at a subset of the 
NHANES sample designed to include individuals who would have been targeted by the 
ACIP recommendations for an HPV catch-up vaccine among females aged 13–26 years. 
This recommendation was adopted in the June 2006 meeting of the ACIP (Markowitz et al., 
2007). Our sample includes females who were age 27 years or younger in 2007–2008 
NHANES cycle, 29 or younger in 2009–2010, 31 or younger in 2011–2012, 33 or younger 
2013–2014, and who were also at least 18-years-old at the time of the survey.
Starting from an initial adult sample size of 24,113, restricting our sample to include only 
females yields a smaller sample size of 12,370. Further restrictions based on the NHANES 
cycles and age groups described above yields an even smaller sample of 2355. Finally, we 
excluded observations of individuals who did not have sex in the last 12 months and who did 
not remember or did not report necessary characteristics for the model such as their 
immunization status, their age of first sexual experience, risky behaviors such as smoking 
and alcohol consumption, or other. These steps resulted in a final sample that contains 991 
individuals with 767 (77%) non-vaccinated and 224 (23%) vaccinated for HPV. This 
corresponds to observation counts from the NHANES cycles of 2007–2008, 2009–2010, 
2011–2012, and 2013–2014 that are equal to 157 individuals with 16 vaccinated and 141 
non-vaccinated, 257 individuals with 46 vaccinated and 211 non-vaccinated, 273 individuals 
with 78 vaccinated and 195 non-vaccinated, and 304 individuals with 84 vaccinated and 220 
non-vaccinated, respectively. The outcomes under consideration are the number of times a 
respondent had sex in the last 12 months and the frequency of condom usage during the last 
12 months. These outcomes were elicited from respondents in a private room using a self-
administered computer-based questionnaire, the Audio Computer Assisted Self Interview 
system. We focus on these outcomes because they represent relatively minor, or marginal, 
changes in sexual behavior when compared to other markers of sexual behavior such as 
acquiring an STI or changing sex partners. In addition, other outcome variables that we 
considered, such as the number of sex partners and the status of any STIs, were not selected 
because including them yielded an even more limited analytical sample size.
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3.1 Common support
Treatment effects should only be estimated using the subsample of observations where the 
estimated propensity score overlaps between the treated and control groups (Crump et al., 
2009; Kaiser and Schmid, 2014). These observations are defined as being from the region of 
common support, p ∈ γ , 1 − γ . We use an established procedure (Crump et al., 2009) to 
estimate the optimal value for γ . Since our empirical approach implements two propensity 
score models, we identify two different values for γ , which is 0.085 for the basic propensity 
model and 0.084 for the expanded propensity model. After dropping observations that did 
not have common support, the basic propensity model yields a sample that contains 589 
(73%) non-vaccinated and 213 (27%) vaccinated individuals (Table 2). The expanded 
propensity model yields a slightly smaller sample that contains 569 (73%) non-vaccinated 
and 209 (27%) vaccinated individuals (Table 2).
3.2 Sample balance
Covariate balance between the treatment and control groups is assessed using the normalized 
difference of means (Table 3). The normalized difference of means is the difference of 
means across the treatment and control groups divided by the standard deviation of the 
pooled treatment and control groups. A normalized difference >0.25 can be used as a 
threshold to identify excessive imbalance across treatment and control groups (Imbens and 
Wooldridge, 2009). The sample balance is acceptable for both propensity models. The 
greatest (absolute value) normalized difference among covariates after balancing with the 
basic propensity model and the expanded propensity model was 0.042 and 0.106, 
respectively (Table 3). An acceptable sample balance means that the observed characteristics 
of the treated and control groups are similar, which makes the inference of an effect of 
vaccination more plausible.
4. Results
We find no evidence that at least one dose of HPV vaccination contributes to changes in 
condom usage among young sexually-active women. Looking at the results for condom 
usage, the estimated ATE is not found to be statistically significant forany of the model 
specifications considered (Table 4). The direction of the estimated ATE, while not 
statistically significant, is negative among higher levels of condom usage and among the 
lowest reported level of condom usage, i.e., for respondents who reported ever using a 
condom, using a condom more than half of the time, or every time they had sex. Among 
respondents who reported condom usage half of the time they had sex, the direction of the 
ATE is less consistent as well as not being found to be statistically significant.
In the models looking at the frequency of sexual encounters, we find inconsistent statistical 
evidence that at least one dose of HPV vaccination contributes to changes in sexual activity 
among young sexually-active women (Table 5). This evidence varies across specifications of 
the propensity and outcomes models. In the majority of the sex frequency models and in 
particular when the outcome represents whether a respondent had sex more than 52 or 104 
times per year, the ATE is not found to be statistically significant. In one subset of models, 
where the outcome is whether a respondent had sex more than 12 times in the last year, the 
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ATE was found to be statistically significant in several models with an estimate ranging 
from 0.055 to 0.071, which implies an individual was 5.5–7.1 percentage points more likely 
to have sex at least 12 times if she received an HPV vaccine. The effect is found to be not 
statistically significant in one model (Basic-Basic), statistically significant at the 0.10 
significance level for three models (Basic-Expanded, Basic-Basic with age fixed effects and 
Expanded-Basic) and the 0.05 level for two models (Expanded-Expanded and Expanded-
Basic with age fixed effects).
5. Discussion
The most important finding from our study is that at least one dose of HPV vaccination does 
not appear to have a substantive effect on the sexual behavior of young sexually-active 
women. This study reinforces the findings of other studies on this topic, which also found 
negligible changes in sexual behavior following vaccination for HPV (Bednarczyk et al., 
2012; Liddon et al., 2012; Smith et al., 2014; Jena et al., 2015). The main contribution of our 
study was the use of a different dataset and a different methodological approach to 
investigate this issue. This study demonstrates the usefulness of propensity-score-based 
methods to assess potential behavioral responses to health interventions that could 
conceivably change health-risk perceptions. The persistence of our result of no discernable 
effect, in spite of this approach, underscores the need to better understand how individuals 
process changes in health-risk.
We hypothesized that a small change in perceived health risk could incentivize a 
proportionally small change in behavior. We also hypothesized that any behavioral response 
to HPV vaccination would be minor, and would thus best be measured in terms of 
incremental changes in behavior. For this reason, we focused on two key changes in 
behavior: condom use and frequency of sex. Given the theoretical grounds for a change in 
sexual behavior after the availability of the HPV vaccine, several plausible reasons remain as 
to why an effect cannot be measured in this study. First, even though the HPV vaccine is 
very effective in preventing adverse health outcomes attributable to HPV, the perceived risk 
of HPV might be small relative to all other STIs, such as HIV and genital herpes. As a 
result, the influence of the HPV vaccine on the perceived health risks associated with sexual 
behavior might be too small to incentivize a change in sexual behavior. Moreover, any 
change in perceived health risk may be even smaller if recipients of the vaccine were 
unfamiliar with HPV or the adverse health outcomes associated with HPV.
A previous study of HPV vaccine impact and effectiveness using NHANES data from the 
early vaccine era (2007–2010) found that the lifetime number of sexual partners appeared to 
be greater among those who received the HPV vaccine, as compared to those not vaccinated 
for HPV (Markowitz et al., 2013). This finding was correlational and the study did not 
assess whether a vaccination leads to changes sexual behavior or whether sexual behavior or 
expected sexual behavior, leads to decisions about vaccination (Rimer et al., 2014). A 
subsequent study that used NHANES data from a later time period found no statistically 
significant association between vaccination status and if a respondent had three or more 
lifetime sexual partners (Markowitz et al., 2016). These studies focused primarily on 
assessing changes in HPV prevalence in the vaccine era and did not investigate condom 
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usage. A recent study found no association between risk perceptions after HPV vaccination 
and riskier sexual behaviors (Mayhew et al., 2014). Another study found low levels of 
knowledge and perceived risks related to HPV and cervical cancer (Denny-Smith et al., 
2006). These findings support the findings in our study and, taken together, might suggest 
that the limited awareness or low perceived risk associated with HPV and cervical cancer 
may at least partially explain the null effect found for HPV vaccination on sexual behavior.
In some model specifications, our study finds a statistically significant treatment effect for 
respondents reporting having sex more than 12 times in the past year (sexTimesAtLeast12). 
These effects were statistically significant at the 10% level in three models and at the 5% 
level in two models. We interpret this result as inconsistent and providing fairly weak 
statistical evidence for a relationship between vaccination and sexual behavior. However, a 
plausible explanation for a relationship could be that low levels of sexual frequency, or any 
other measurements that would reflect sexual inexperience may be more sensitive to changes 
in sex-related health risks than other outcomes. The other two measures of frequency of sex 
(>52 and >104 times in the past year) that we investigated might only be able to detect 
behavioral changes among individuals with more sexual experience, similar to individuals 
with a higher frequency of sexual encounters, higher numbers of sexual partners, or 
diagnosis with other STIs. An individual with a greater amount of sexual experience may 
perceive a smaller change in health risk following an HPV vaccination than an individual 
who is less experienced sexually. Both the outcome groups investigated in this study, 
condom use and frequency of sex, were contingent on a respondent having reported having 
had sex at least one time in the last 12 months. As a result, this study could assess frequency 
of sexual behaviors, but not assess initiation of sexual activity.
Data from NHANES is published in 2-year cycles, so the exact age in a given year, for 
example, the age of a respondent at June 2006 is not known with perfect precision. While we 
designed our sample to include the most individuals who were plausibly in the target age 
range of the first ACIP recommendation on HPV vaccination, in some cases an individual 
could be included in our sample who was not subject to the recommendations. As an 
example, a woman who was 27 in the 2007–2008 NHANES cycle may have turned 27 
before the ACIP recommendation was approved in June 2006. We conducted a sensitivity 
analysis, where the maximum age from each NHANES cycle was reduced by 1 year (26 or 
younger in 2007–2008 NHANES cycle, 28 or younger in 2009–2010 NHANES cycle, etc.), 
and this more restrictive age requirement had no qualitative impact on our results. Data 
analyzed in this study are from respondent reports, and respondents may not have perfect 
recall regarding their history of vaccinations, sexual activity, or other relevant behaviors. 
Additional sexual behavior variables, such as the history of STIs and the number of sexual 
partners, were considered as outcome variables, but these variables were not selected due to 
relatively lower response rates for those questions compared with the condom use and sex 
frequency questions, which resulted in analytical samples too small for inference.
Since the exact date of the vaccination is unknown, this analysis does have a potential 
endogeneity issue, where we cannot ensure the temporality of the assumed causal pattern. At 
least some number of individuals in our dataset were likely to have received their HPV 
vaccine in the last 12 months, which would imply that their reported sexual behaviors 
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represent their decisions, circumstances and risk-perceptions prior to receiving the vaccine. 
The nature of the questions asked in NHANES offers some assurance that the majority of 
vaccinations occur prior to surveyed sexual activities of the outcomes variables. In 
particular, the NHANES question about HPV vaccination elicited if a vaccination had ever 
occurred whereas for the outcome variables the survey elicited behaviors that occurred in the 
last 12 months. Data from the 2008 to 2014 National Health Interview Surveys indicate that 
the average annual increase in HPV vaccination coverage among females who were 19–26-
years-old in 2007 or 2008 was 13% and may have been as great as 56% of vaccinated 
individuals, with higher values found among cohorts in earlier survey years (from 2008 and 
2009) and among older females (aged 23–26) (O’Halloran et al., 2016). To evaluate this 
potential source of bias, in the Supplemental Appendix we included sensitivity analyses, 
where the earlier cycles of NHANES were excluded from the analytical dataset. These 
sensitivity analyses showed qualitatively similar results as those presented in the main text. 
In a related issue, any behavioral responses to HPV immunization may occur or may be 
stronger after having received the complete dosing series of the HPV vaccine. Our study 
focused on whether a respondent reported receiving at least one dose of an HPV vaccine, not 
the complete series. Finally, immunization programs and sexual education curriculum can 
vary across states. These state-level practices may have a strong impact on sexual behavior 
and any behavior response to receiving a vaccine. Unfortunately, state-level variables are not 
available in the NHANES public use datasets used in this study. Furthermore, due to the 
probabilistic sampling method used by NHANES, the number of locations where NHANES 
data is collected is somewhat small during any given NHANES cycle, so there is unlikely to 
be substantial variation in any state-level indicators or variables. Investigations into any 
effect of state-level practices would be a worthwhile area for future research.
In this study, both vaccination status and the sexual behavior outcomes were self-reported. In 
the case of vaccination status, one previous study found a reasonable amount of concordance 
between self-reported vaccination status of the HPV vaccine among 18–26-year-olds, when 
compared to vaccination status documented in electronic health records (Rolnick et al., 
2013). A number of studies have investigated self-reported condom usage with biological 
measures of unprotected sexual activity (Rose et al., 2009) and incidence of sexually 
transmitted diseases (Weir et al., 1999; Gallo et al., 2007). In general, studies assessing the 
validity of self-reported condom use found less concordance than was found in the HPV 
vaccination study. However, the studies on the validity of self-reported condom use 
investigated populations that were from smaller geographic areas, included adolescents and 
were at higher risk for STIs, and so may have different self-reporting tendencies than the 
general population. Possible measurement error stemming from self-reported data is a 
common limitation among survey-based research, particularly when the survey is conducted 
across several years and sampled from a nation-wide population.
In spite of these limitations, this study provides empirical evidence on the relationship 
between HPV vaccination and sexual behavior. With results that comport well with other 
results in the literature, this study finds no apparent effect of HPV vaccine receipt on the 
sexual behavior of young sexually-active women.
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Figure 1. 
Conceptual diagram of HPV vaccination and risky behavior model.
HAV refers to hepatitis A virus; HBV refers to hepatitis B virus; HPV refers to human 
papillomavirus.
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Table 1.
Description of data compiled from the National Health and Nutrition Examination Surveys from 2007 to 2014
Variable group Variable name Values
HPV vaccine status hpvVax 1 if vaccinated; 0 if not vaccinated
Age age Age in years
Race/ethnicity white 1 if white, non-Hispanic; 0 otherwise
black 1 if black, non-Hispanic; 0 otherwise
hispanic 1 if Hispanic; 0 otherwise
other 1 if not white, black or Hispanic; 0 otherwise
Schooling gradHighSchool 1 if completed grade 12th; 0 otherwise
gradCollege 1 if completed college; 0 otherwise
Income relative to poverty line eqOrAbPovLine 1 if income ⩾ Poverty line; 0 otherwise
eqOrAb2×PovLine 1 if income ⩾ 2 × Poverty line; 0 otherwise
eqOrAb3×PovLine 1 if income ⩾ 3 × Poverty line; 0 otherwise
Insurance status anyInsurance 1 if covered by any insurance or payer; 0 otherwise
medicaid 1 if covered by Medicaid; 0 otherwise
Immunization history havVax 1 if ever received the hepatitis A vaccine; 0 otherwise
anyHbv 1 if ever received any dose of hepatitis B vaccine; 0 otherwise
allHbv 1 if received all doses of hepatitis B vaccine; 0 otherwise
Other factors related to health system utilization birthControlPills 1 if ever used birth control pills; 0 otherwise
hivTest 1 if ever been tested for HIV/AIDS; 0 otherwise
routineHealth 1 if have at least one routine place to go for healthcare; 0 otherwise
Partner status married 1 if married; 0 otherwise
partnered 1 if partnered and not married; 0 otherwise
Other behavioral factors everDrinkAlc 1 if ever drank alcohol; 0 otherwise
drinksPerDay Average number of alcohol drinks per day
smoked100Cigarettes 1 if ever smoked 100 cigarettes; 0 otherwise
smokesEveryDay 1 if smokes cigarettes every day; 0 otherwise
everMarijuana 1 if ever smoked marijuana; 0 otherwise
ageFirstSex Age in years when first had sex
Temporal effects year0708 1 if NHANES cycle is 2007–2008; 0 otherwise
year0910 1 if NHANES cycle is 2009–2010; 0 otherwise
year1112 1 if NHANES cycle is 2011–2012; 0 otherwise
biannualTrend Trend corresponding with 2 year NHANES cycles
Number of times had sex during last 12 monthsa sexTimesAtLeast12 1 if number of times had sex ⩾ 12; 0 otherwise
sexTimesAtLeast52 1 if number of times had sex ⩾ 52; 0 otherwise
sexTimesAtLeast104 1 if number of times had sex ⩾ 104; 0 otherwise
Condom usage during last 12 monthsb everUseCondom 1 if used a condom at least once; 0 otherwise
halfUseCondom 1 if used a condom half of the time; 0 otherwise
mostUseCondom 1 if used a condom most of the time; 0 otherwise
alwaysUseCondom 1 if used a condom always; 0 otherwise
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aVerbatim question from NHANES: ‘In the past 12 months, about how many times have you had (vaginal or anal/vaginal/anal) sex?’ Possible 
responses to this question were categorical: ‘Never’, ‘Once’, ‘2–11 times’, ‘12–51 times’, ‘52–103 times’, ‘104–364 times’, ‘365 times or more’, 
‘Refused’ to give a response, and ‘Don’t know’.
bVerbatim question from NHANES: ‘In the past 12 months, about how often have you had (vaginal or anal/vaginal/anal) sex without using a 
condom?’ Possible responses to this question were categorical: ‘Never’, ‘Less than half of the time’, ‘About half of the time’, ‘Not always, but 
more than half of the time’, ‘Always’, ‘Refused’ to give a response, and ‘Don’t know’. To simplify interpretation, the responses for this question 
were converted to values indicating the portion of times the respondent had sex with a condom, as opposed to without a condom. HPV refers to 
human papillomavirus.
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Table 3.
Balance table results after weighting for the inverse probability of treatment, using two propensity models, 
Basic and Expanded
Propensity model
Basic Expanded
Variable name Normalized differencea P valueb Normalized differencea P valueb
age 0.004 0.970 −0.082 0.427
white REF REF REF REF
black 0.004 0.964 0.024 0.792
hispanic −0.042 0.561 −0.022 0.755
other 0.035 0.711 −0.074 0.326
gradHighSchool −0.026 0.809 −0.020 0.859
gradCollege 0.004 0.975
eqOrAbPovLine −0.031 0.691 −0.038 0.617
eqOrAb2×PovLine −0.030 0.744
eqOrAb3×PovLine 0.010 0.911
anyInsurance −0.010 0.934 −0.032 0.789
medicaid 0.005 0.966
everUseBirthControl −0.025 0.838 −0.041 0.734
hivTest 0.022 0.818 −0.044 0.656
havVax −0.005 0.967 −0.045 0.706
anyHbv −0.009 0.940 −0.063 0.625
allHbv −0.033 0.793
routineHealth 0.021 0.824
married 0.024 0.833 −0.106 0.288
partnered 0.037 0.792
everDrinkAlc −0.023 0.832 −0.007 0.941
drinksPerDay 0.009 0.918
smoked100Cigarettes 0.014 0.879 0.056 0.526
smokesEveryDay 0.051 0.633
everMarijuana 0.034 0.748
ageFirstSex 0.022 0.841 0.024 0.814
year0708 0.059 0.700
year0910 −0.007 0.951
year1112 0.010 0.927
year1314 REF REF
biannualTrend −0.029 0.807
aNormalized difference is the difference between vaccinated and not vaccinated means, divided by the pooled standard deviation.
b
Differences in means between the weighted vaccinated and unvaccinated samples were tested using t-test with p values reported. REF refers the 
referent variable of the categorical group of variables.
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Table 4.
Estimated effects on HPV vaccination status with respect to outcome variables on condom usage from a 
doubly robust estimation procedure
Propensity
model
Outcome: everUseCondom halfUseCondom
Outcome modela ATEb SE P value ATE SE P value
Basic Basic −0.024 0.041 0.561 −0.025 0.040 0.547
Basic Expanded −0.026 0.039 0.512 −0.019 0.039 0.633
Basic Basic w sex times −0.015 0.041 0.718 −0.012 0.039 0.772
Basic Basic w age FEs −0.010 0.039 0.804 −0.016 0.036 0.670
Expanded Basic −0.008 0.040 0.856 0.008 0.040 0.851
Expanded Expanded −0.019 0.040 0.654 −0.003 0.040 0.937
Expanded Basic w sex times −0.001 0.040 0.987 0.020 0.040 0.631
Expanded Basic w age FEs −0.005 0.039 0.907 0.006 0.037 0.881
mostUseCondom alwaysUseCondom
Basic Basic −0.033 0.042 0.439 −0.037 0.033 0.258
Basic Expanded −0.028 0.042 0.518 −0.037 0.030 0.218
Basic Basic w sex times −0.021 0.040 0.612 −0.032 0.033 0.327
Basic Basic w age FEs −0.019 0.039 0.645 −0.036 0.030 0.241
Expanded Basic −0.045 0.039 0.249 −0.032 0.032 0.315
Expanded Expanded −0.056 0.040 0.161 −0.037 0.031 0.233
Expanded Basic w sex times −0.033 0.039 0.415 −0.026 0.032 0.426
Expanded Basic w age FEs −0.034 0.037 0.360 −0.032 0.031 0.305
aThe basic outcome model includes as covariates: black, hispanic, other, age, gradHighSchool, married, eqOrAbPovLine, anyInsurance, 
birthControlPills, hivTest, everDrinkAlc, drinksPerDay, smoked100Cigarettes, smokesEveryDay, ageFirstSex, biannualTrend. The expanded 
outcome model includes as covariates: black, hispanic, other, age, gradHighSchool, gradCollege, married, partnered, eqOrAbPovLine, 
eqOrAb2xPovLine, eqOrAb3xPovLine, anyInsurance, routineHealth, birthControlPills, hivTest, everDrinkAlc, drinksPerDay, 
smoked100Cigarettes, smokesEveryDay, everMarijuana, ageFirstSex, year0708, year0910. The basic w sex times outcome model includes all the 
covariates of the basic model and the following: sexTimesAtLeast12, sexTimesAtLeast52, sexTimesAtLeast104. The basic w age FEs outcome 
model includes all the covariates of the basic model and indicator variables for each age level in years.
b
The average treatment effects were calculated using doubly robust estimator.
HPV refers to human papillomavirus; ATE refers to average treatment effect; SE refers to standard error; FEs refers to fixed effects.
Health Econ Policy Law. Author manuscript; available in PMC 2020 November 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Leidner et al. Page 24
Table 5.
Estimated effects on HPV vaccination status with respect to outcome variables on frequency of sex, measured 
as the number of times a person had sex in the last 12 months, using a doubly robust estimation procedure
Outcome sexTimesAtLeast12 sexTimesAtLeast52
Propensity model Outcome modela ATEb SE P value ATE SE P value
Basic Basic 0.055 0.035 0.115 0.010 0.044 0.836
Basic Expanded 0.058 0.033 0.082* 0.014 0.043 0.749
Basic Basic w age Fes 0.061 0.031 0.052* 0.018 0.044 0.700
Expanded Basic 0.068 0.035 0.052* 0.015 0.050 0.777
Expanded Expanded 0.071 0.034 0.035** 0.017 0.050 0.742
Expanded Basic w age FEs 0.071 0.032 0.028** 0.014 0.048 0.777
sexTimesAtLeast104
Basic Basic −0.009 0.036 0.825
Basic Expanded −0.005 0.036 0.897
Basic Basic w age Fes −0.010 0.035 0.778
Expanded Basic −0.019 0.038 0.638
Expanded Expanded −0.014 0.038 0.720
Expanded Basic w age FEs −0.019 0.037 0.625
aThe basic outcome model includes as covariates: black, hispanic, other, age, gradHighSchool, married, eqOrAbPovLine, anyInsurance, 
birthControlPills, hivTest, everDrinkAlc, drinksPerDay, smoked100Cigarettes, smokesEveryDay, ageFirstSex, biannualTrend. The expanded 
outcome model includes as covariates: black, hispanic, other, age, gradHighSchool, gradCollege, married, partnered, eqOrAbPovLine, 
eqOrAb2xPovLine, eqOrAb3xPovLine, anyInsurance, routineHealth, birthControlPills, hivTest, everDrinkAlc, drinksPerDay, 
smoked100Cigarettes, smokesEveryDay, everMarijuana, ageFirstSex, year0708, year0910. The basic w age FEs outcome model includes all the 
covariates of the basic model and indicator variables for each age level in years.
b
The average treatment effects were calculated using double-robust estimator.
HPV refers to human papillomavirus; ATE refers to average treatment effect; SE refers to standard error; FEs refer to fixed effects.
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